Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards  

作　　者：Michael Horowitz Lu Cai Md Shahidul Islam 

机构地区：[1]Department of Medicine,University of Adelaide,Adelaide 5005,Australia [2]Pediatric Research Institute,University of Louisville,Louisville,KY 40202,United States [3]Department of Biochemistry,School of Life Sciences,University of KwaZulu-Natal,Durban 4000,KwaZulu-Natal,South Africa

出　　处：《World Journal of Diabetes》2024年第3期326-330,共5页世界糖尿病杂志（英文版）（电子版）

摘　　要：This editorial is stimulated by the article by Alqifari et al published in the World Journal of Diabetes(2024).Alqifari et al focus on practical advice for the clinical use of glucagon-like-peptide-1(GLP-1)receptor agonists(GLP-1RAs)in the management of type 2 diabetes and this editorial provides complementary information.We initially give a brief historical perspective of the development of GLP-1RAs stimulated by recognition of the‘incretin effect’,the substantially greater insulin increase to enteral when compared to euglycaemic intravenous glucose,and the identification of the incretin hormones,GIP and GLP-1.In addition to stimulating insulin,GLP-1 reduces postprandial glucose levels by slowing gastric emptying.GLP-1RAs were developed because native GLP-1 has a very short plasma half-life.The majority of current GLP-1RAs are administered by subcutaneous injection once a week.They are potent in glucose lowering without leading to hypoglycaemia,stimulate weight loss in obese individuals and lead to cardiovascular and renal protection.The landscape in relation to GLP-1RAs is broadening rapidly,with different formulations and their combination with other peptides to facilitate both glucose lowering and weight loss.There is a need for more information relating to the effects of GLP-1RAs to induce gastrointestinal symptoms and slow gastric emptying which is likely to allow their use to become more effective and personalised.

关 键 词：Glucagon-like-peptide-1 Glucose-dependent insulinotropic peptide Gastric emptying Type 2 diabetes 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]